ABSCIENCES (EPA:AB) | Finanzwire

Basculer en Français

10108	Companies
207163	Keywords
137293	Articles
109799	Press releases

Home
Companies
ABSCIENCES

PRESS RELEASE

published on 10/16/2025 at 20:57, 5 months 12 days ago

AB Science provides intitial Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
AB Science provides initial Phase 1 data for combination of AB8939 with Venetoclax for refractory or relapsed Acute Myeloid Leukemia. Promising results incl. 100% disease control rate and 100% response rate

AB Science AB8939 Phase 1 Data AML Venetoclax
BRIEF

published on 10/14/2025 at 08:41, 5 months 15 days ago

AB Science Reports Promising Initial Data from AML Study

Clinical Trial AML Treatment AB Science AB8939 Venetoclax
PRESS RELEASE

published on 10/14/2025 at 08:36, 5 months 15 days ago

AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939
AB Science releases positive initial data on combination treatment of AB8939 with Venetoclax for refractory or relapsed Acute Myeloid Leukemia (AML), showing promising results in patients with unfavorable genetic profiles. Virtual conference scheduled with renowned experts in AML

Virtual Conference AB Science AB8939 AML Venetoclax
BRIEF

published on 08/04/2025 at 08:03, 7 months 25 days ago

AB Science Completes EUR 2.55 Million Private Placement

Private Placement Shareholders Clinical Development AB Science EUR 2.55 Million
PRESS RELEASE

published on 08/04/2025 at 07:58, 7 months 25 days ago

AB Science announces the successful completion of a 2.55 million euros private placement
AB Science successfully completes EUR 2.55 million private placement to fund clinical development. New shares issued with warrants attached

Private Placement Shareholders Clinical Development AB Science EUR 2.55 Million
BRIEF

published on 07/30/2025 at 07:50, 7 months 30 days ago

AB Science Advances in AML Study With New European Approvals

Regulatory Approval Market Potential AB8939 Venetoclax AML Study
PRESS RELEASE

published on 07/30/2025 at 07:45, 7 months 30 days ago

AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML
AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining AB8939 with venetoclax for treatment of acute myeloid leukemia

Regulatory Approval AB Science AB8939 Venetoclax Phase I/II Study
BRIEF

published on 07/24/2025 at 08:01, 8 months 5 days ago

AB Science Gains Approval for Phase 3 ALS Masitinib Study Across Europe

Phase 3 Trial ALS AB Science Masitinib European Approval
PRESS RELEASE

published on 07/24/2025 at 07:56, 8 months 5 days ago

AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS
AB Science receives approval from European countries to initiate Phase 3 study of masitinib in ALS following protocol validation by EMA and FDA

Phase 3 Study ALS AB Science Masitinib EMA
BRIEF

published on 07/08/2025 at 08:06, 8 months 21 days ago

AB Science Completes EUR 1.925 Million Private Placement

Private Placement Share Issuance Biotech Funding AB Science AB8939 Program

Accesswire

Published on 03/29/2026 at 12:15, 2 hours 34 minutes ago

China Xlx Announces 2025 Annual Results Deepening Efforts in Reducing Costs, Enhancing Efficiency, Strengthening Competitiveness Through Differentiation and Driving Marketing Transformation
Published on 03/28/2026 at 01:00, 1 day 12 hours ago

Battery X Metals Announces Confidential Submission of Amended Draft Registration Statement with the U.S. Securities and Exchange Commission in Connection with Proposed U.S. National Securities Exchange Initial Public Offering
Published on 03/28/2026 at 00:55, 1 day 12 hours ago

Notification of Relevant Change to Significant Shareholder
Published on 03/28/2026 at 00:50, 1 day 12 hours ago

"Rise" Selected as NASA Artemis II Moon Mascot
Published on 03/27/2026 at 22:45, 1 day 15 hours ago

Caledonia Mining Corporation Plc - Notification of Relevant Change to Significant Shareholder

View all ACCESSWIRE

EQS Group

Published on 03/28/2026 at 10:05, 1 day 4 hours ago

Hisense Advances a Quiet Green Revolution in Home Entertainment
Published on 03/28/2026 at 08:56, 1 day 5 hours ago

Turkiye Garanti Bankasi A.S.: Sale of Garanti Bank S.A. and our public disclosure dated 10.03.2026
Published on 03/28/2026 at 01:42, 1 day 12 hours ago

EQS-Adhoc: Raiffeisen Bank International AG: Agreement on the acquisition of Garanti BBVA Group Romania
Published on 03/27/2026 at 21:58, 1 day 15 hours ago

Kaufman & Broad SA: Availability of the Universal Registration Document 2025
Published on 03/27/2026 at 20:08, 1 day 17 hours ago

EQS-Adhoc: CECONOMY AG: Information on the ongoing public takeover process – uncertainty regarding FDI clearance in Austria

Les Echos

Published on 03/27/2026 at 19:06, 1 day 18 hours ago

Mersen: Disclosure of trading own shares
Published on 03/27/2026 at 18:52, 1 day 18 hours ago

Crédit Agricole CIB announces the publication of its 2025 Universal Registration Document
Published on 03/27/2026 at 18:40, 1 day 19 hours ago

2026 share capital increase reserved for members of the Saint-Gobain Group employee savings plan
Published on 03/27/2026 at 17:53, 1 day 19 hours ago

Publication of Carrefour's 2025 Universal Registration Document
Published on 03/27/2026 at 17:45, 1 day 20 hours ago

PUBLICATION OF THE UNIVERSAL REGISTRATION DOCUMENT FISCAL YEAR 2025

View all LES ECHOS COMFI WIRE